About Thioredoxin-dependent peroxide reductase, mitochondrial
Thioredoxin-dependent peroxide reductase, mitochondrial (PRDX3) is a protein
from Homo sapiens identified by UniProt accession
P30048, 256 residues long.
MolForge cross-references it against 0 known binders and
228 disease associations.
Target properties
| Protein name | Thioredoxin-dependent peroxide reductase, mitochondrial |
|---|
| UniProt accession | P30048 |
|---|
| Gene | PRDX3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 256 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (228)
Diseases linked to this target (Open Targets).
- corneal dystrophy, punctiform and polychromatic pre-descemet · score 0.52
- autosomal recessive cerebellar ataxia · score 0.27
- neurodegenerative disease · score 0.26
- genetic disorder · score 0.19
- cerebellar ataxia · score 0.18
- neutrophil count · score 0.10
- lymphocyte count · score 0.09
- mean platelet volume · score 0.08
- carpal tunnel syndrome · score 0.08
- benign prostatic hyperplasia · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P30048-F1 | alphafold | PREDICTED | 84.74 | — |
Amino-acid sequence (256 residues)
MAAAVGRLLR ASVARHVSAI PWGISATAAL RPAACGRTSL TNLLCSGSSQ AKLFSTSSSC HAPAVTQHAP YFKGTAVVNG EFKDLSLDDF KGKYLVLFFY PLDFTFVCPT EIVAFSDKAN EFHDVNCEVV AVSVDSHFSH LAWINTPRKN GGLGHMNIAL LSDLTKQISR DYGVLLEGSG LALRGLFIID PNGVIKHLSV NDLPVGRSVE ETLRLVKAFQ YVETHGEVCP ANWTPDSPTI KPSPAASKEY FQKVNQ
Explore Thioredoxin-dependent peroxide reductase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets